Sarah Holland joins the Cureteq team as Chief Business Officer.
Sarah brings over 30 years of biopharma industry experience, spanning the full value chain from R&D, Commercial and Business Development. Sarah worked most recently as CBO of VectivBio, and prior to that as Global Head of Licensing and Head of Bio R&D at Lonza.
She led the External Science and Partnering team at Sanofi and before that held positions of increasing responsibility with Roche for over a decade, with notable deals in oncology and CNS while building the M&A assessment and integration team. In her capacity of CBO, Sarah will be a critical addition to the team as we are gearing up for further growing the pipeline.
For setting up meeting at J.P. Morgan 2024, San Francisco
